Related Experiment Video
Updated: Jan 30, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Treatment pathways of lung cancer patients in the Czech Republic: insights from administrative claims data
Aleš Tichopád1, Gleb Donin2, Marian Rybár2
1Department of Biomedical Technology, Czech Technical University in Prague, Faculty of Biomedical Engineering, Praha, Czech Republic ales.tichopad@gmail.com.
Introduction:
A patient pathway is an evidence-based tool that details the phases of care with the aim of increasing the effectiveness and efficiency of patient care. We describe diagnostic and treatment pathways and related overall survival (OS) of non-small cell lung cancer patients.
Methods:
This was a longitudinal, historical descriptive cohort study based on administrative claim data, spanning from 2017 to 2022. The index date was determined by the first bronchoscopy with lung biopsy (BX) followed by histopathological (HP) examination, alongside the presence of the International Classification of Diseases 10th revision diagnosis code C34. Incident patients aged ≥18 without prior malignancy. Pharmacotherapies (PHT), including chemotherapy (PHT_CT), precision therapy (PHT_IOTT), as well as surgery (SX) and radiotherapy (RT), were investigated associated with OS. A presence of multidisciplinary team (MDT) and treatment at a Complex Oncological Center (COC) with high-load experience was considered.
Results:
We analysed 5819 patient pathways. Less than half (45.6%) of patients had MDT reported within a median of 20 days. Of the 4417 patients treated, 30% underwent more than one BX, 47.7% received PHT_CT, 25.9% underwent SX, 16.4% underwent RT and 9.08% PHT_IOTT. Early initiation of treatment within 4 weeks from BX was identified in 21% of SX patients, 30% of patients treated with PHT_CT and 23% of RT patients. The centralisation of care in COCs primarily concerned SX and PHT_IOTT, while 33% of patients indicated to PHT_CT were treated elsewhere. The median OS reached approximately 16 months in the overall population, 21 months in the verified treated cohort and 13 months in patients treated with PHT_CT, while it was not reached in patients treated with SX. We observed a positive association between patient prognosis and treatment centralisation in COCs.
Conclusions:
This methodology can be implemented as a technical infrastructure to fulfil the organisation and quality evaluation routines in cancer care, largely based on administrative data.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
08:49Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Related Concept Videos
02:56Treatment Resistant Cancers
01:11Testing a Claim about Mean: Known Population SD
Estimating a population mean requires the samples to be distributed normally. The data should be collected from the randomly selected samples having no sampling bias. The sample size needed to be higher than 30, and most importantly, the population standard deviation should be already known.
In most realistic situations, the population standard deviation is often unknown, but in rare circumstances, when it...
01:24Testing a Claim about Population Proportion
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
01:19Testing a Claim about Standard Deviation
The hypothesis testing for the claim of population standard deviation (or variance) requires the data and samples to be random and unbiased. The population distribution also must be normal. There is no specific requirement on the sample size as the estimation is based on the chi-square distribution.
As a first step, the hypothesis (null and alternative) concerning the claim about...
01:21Testing a Claim about Mean: Unknown Population SD
Estimating a population mean requires the samples to be approximately normally distributed. The data should be collected from the randomly selected samples having no sampling bias. There is no specific requirement for sample size. But if the sample size is less than 30, and we don't know the population standard deviation, a different approach is used;...
01:47Lung Capacity